NCT05880082View on ClinicalTrials.gov

PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

118

Participants

Timeline

Start Date

January 13, 2023

Primary Completion Date

August 18, 2025

Study Completion Date

August 18, 2025

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG

Tislelizumab

Tislelizumab 200mg, Q3W, 2-4 cycles Albumin paclitaxel 240 mg/m², adjusted according to the patient Carboplatin: AUC=5 Q3W, d1 or cisplatin: 20mg/m² iv, D1-3 Q3W or Nedaplatin: 70mg d1 Q3W

Trial Locations (1)

400042

Army Medical Center of the People's Liberation Army, Chongqing

All Listed Sponsors

lead

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

OTHER